Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorLOPES, Nilceia
dc.contributor.authorDIAS, Leticia L. S.
dc.contributor.authorAZULAY-ABULAFIA, Luna
dc.contributor.authorOYAFUSO, Luiza K. M.
dc.contributor.authorSUAREZ, Maria Victoria
dc.contributor.authorFABRICIO, Lincoln
dc.contributor.authorKOBATA, Clarice Marie
dc.contributor.authorCESTARI, Tania
dc.contributor.authorGONTIJO, Bernardo
dc.contributor.authorSABBAG, Cid Y.
dc.contributor.authorANTONIO, Joao R.
dc.contributor.authorROMITI, Ricardo
dc.contributor.authorPERTEL, Patricia C.
dc.date.accessioned2019-11-06T18:51:56Z
dc.date.available2019-11-06T18:51:56Z
dc.date.issued2019
dc.description.abstractIntroduction Psoriasis is an immune-mediated, chronic, inflammatory disease, which has a substantial humanistic and economic burden. This study aimed to assess the impact of this disease on health-related quality of life (HRQoL), work productivity, and direct and indirect costs from a societal perspective among Brazilian patients. Methods This is a cross-sectional, observational, multicenter study, enrolling patients with moderate to severe plaque psoriasis according to physician evaluation. Data collection was performed from December 2015 to November 2016 through face-to-face interviews using a structured questionnaire and five standardized patient-reported outcomes instruments. Direct costs were estimated by multiplying the amount of resources used (12-month recall period) by the corresponding unit cost. Indirect costs were grouped in two time horizons: annual costs (income reduction and absenteeism) and lifetime costs (demission and early retirement). Results A total of 188 patients with moderate to severe plaque psoriasis were included, with mean age of 48.0 (SD 13.1). ""Anxiety and depression"" and ""pain and discomfort"" were the most impaired dimensions, according to the EuroQol Five-Dimension-Three-Level (EQ-5D-3L). The highest effect was found for ""symptoms and feelings"" [mean (SD) 2.4 (1.7)] Dermatology Life Quality Index (DLQI) subscale. Psoriatic arthritis (PsA) presence and biologic-naive status were associated with worse HRQoL. Presenteeism was more frequent than absenteeism, according to the Work Productivity and Activity Impairment questionnaire-General Health (WPAI-GH) [17.4% vs. 6.3%], while physical demands and time management were the most affected Work Limitations Questionnaire (WLQ) subscales [means (SD) 23.5 (28.5) and 17.7 (24.9), respectively]. The estimated annual cost per patient was USD 4034. Direct medical costs accounted for 87.7% of this estimate, direct non-medical costs for 2.4%, and indirect costs for 9.9%. Conclusions Results evidenced that moderate to severe plaque psoriasis imposes substantial costs to society. Our data showed that this disease negatively affects both work productivity and HRQoL of Brazilian patients. Subgroups with PsA and biologic-naive patients presented lower HRQoL, showing the impact of this comorbidity and the relevance of biologics in psoriasis treatment. Funding Novartis Biociencias S.A.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipNovartis Biociencias S.A.
dc.identifier.citationADVANCES IN THERAPY, v.36, n.10, p.2849-2865, 2019
dc.identifier.doi10.1007/s12325-019-01049-7
dc.identifier.eissn1865-8652
dc.identifier.issn0741-238X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/34166
dc.language.isoeng
dc.publisherSPRINGEReng
dc.relation.ispartofAdvances in Therapy
dc.rightsopenAccesseng
dc.rights.holderCopyright SPRINGEReng
dc.subjectCost of illnesseng
dc.subjectDermatologyeng
dc.subjectProductivityeng
dc.subjectPsoriasiseng
dc.subjectQuality of Lifeeng
dc.subject.otherquality-of-lifeeng
dc.subject.othercare resource useeng
dc.subject.otherwork productivityeng
dc.subject.otherhospital anxietyeng
dc.subject.otherdepression scaleeng
dc.subject.otherindex dlqieng
dc.subject.otherarthritiseng
dc.subject.othereuroqoleng
dc.subject.otherburdeneng
dc.subject.othercosteng
dc.subject.wosMedicine, Research & Experimentaleng
dc.subject.wosPharmacology & Pharmacyeng
dc.titleHumanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazileng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalLOPES, Nilceia:Novartis Biociencias SA, Sao Paulo, Brazil
hcfmusp.author.externalDIAS, Leticia L. S.:ANOVA Consultoria Saude, Rio De Janeiro, Brazil
hcfmusp.author.externalAZULAY-ABULAFIA, Luna:Inst Dermatol & Estet Brasil Ltda, Rio De Janeiro, Brazil
hcfmusp.author.externalOYAFUSO, Luiza K. M.:Fac Med ABC, Santo Andre, Brazil
hcfmusp.author.externalSUAREZ, Maria Victoria:Hosp Servidor Publ Municipal, Sao Paulo, Brazil
hcfmusp.author.externalFABRICIO, Lincoln:Hosp Univ Evangel Curitiba, Curitiba, Parana, Brazil
hcfmusp.author.externalKOBATA, Clarice Marie:Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil
hcfmusp.author.externalCESTARI, Tania:Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil
hcfmusp.author.externalGONTIJO, Bernardo:Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil
hcfmusp.author.externalSABBAG, Cid Y.:Ctr Paulista Invest Clin & Serv Med Ltda, CEPIC, Sao Paulo, Brazil
hcfmusp.author.externalANTONIO, Joao R.:Fundacao Fac Reg Med Sao Jose Do Rio Preto, Sao Jose Do Rio Preto, Brazil
hcfmusp.author.externalPERTEL, Patricia C.:Novartis Biociencias SA, Sao Paulo, Brazil
hcfmusp.citation.scopus14
hcfmusp.contributor.author-fmusphcRICARDO ROMITI
hcfmusp.description.beginpage2849
hcfmusp.description.endpage2865
hcfmusp.description.issue10
hcfmusp.description.volume36
hcfmusp.origemWOS
hcfmusp.origem.pubmed31432463
hcfmusp.origem.scopus2-s2.0-85071259590
hcfmusp.origem.wosWOS:000488950000021
hcfmusp.publisher.cityNEW YORKeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceBalogh O, 2014, EUR J HEALTH ECON, V15, pS101, DOI 10.1007/s10198-014-0599-zeng
hcfmusp.relation.referenceBoccuzzi SJ, 2003, CONTEMP CARDIOL, P63eng
hcfmusp.relation.referenceBoehncke WH, 2015, LANCET, V386, P983, DOI 10.1016/S0140-6736(14)61909-7eng
hcfmusp.relation.referenceBrooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6eng
hcfmusp.relation.referenceBurgos-Pol R, 2016, ACTAS DERMO-SIFILOGR, V107, P577, DOI 10.1016/j.ad.2016.04.018eng
hcfmusp.relation.referenceCarrascosa JM, 2006, J EUR ACAD DERMATOL, V20, P840, DOI 10.1111/j.1468-3083.2006.01659.xeng
hcfmusp.relation.referenceChan B, 2009, J CUTAN MED SURG, V13, P192, DOI 10.2310/7750.2009.08068eng
hcfmusp.relation.referenceCiconelli Rozana Mesquita, 2006, Sao Paulo Med. J., V124, P325, DOI 10.1590/S1516-31802006000600005eng
hcfmusp.relation.referencede Korte J, 2004, J INVEST DERM SYMP P, V9, P140, DOI 10.1046/j.1087-0024.2003.09110.xeng
hcfmusp.relation.referenceDiBonaventura M, 2018, AN BRAS DERMATOL, V93, P197, DOI 10.1590/abd1806-4841.20186069eng
hcfmusp.relation.referenceDolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002eng
hcfmusp.relation.referenceDriessen RJB, 2010, BRIT J DERMATOL, V162, P1324, DOI 10.1111/j.1365-2133.2010.09693.xeng
hcfmusp.relation.referenceFINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.xeng
hcfmusp.relation.referenceGoncalves DA, 2014, CAD SAUDE PUBLICA, V30, P623, DOI 10.1590/0102-311X00158412eng
hcfmusp.relation.referenceHerrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4eng
hcfmusp.relation.referenceHorn EJ, 2007, J AM ACAD DERMATOL, V57, P963, DOI 10.1016/j.jaad.2007.07.023eng
hcfmusp.relation.referenceKossakowska MM, 2010, J EUR ACAD DERMATOL, V24, P429, DOI 10.1111/j.1468-3083.2009.03432.xeng
hcfmusp.relation.referenceLerner D, 2001, MED CARE, V39, P72, DOI 10.1097/00005650-200101000-00009eng
hcfmusp.relation.referenceLevy AR, 2012, INT J DERMATOL, V51, P1432, DOI 10.1111/j.1365-4632.2011.05359.xeng
hcfmusp.relation.referenceLiang Y, 2017, CURR OPIN IMMUNOL, V49, P1, DOI 10.1016/j.coi.2017.07.007eng
hcfmusp.relation.referenceMartins BDL, 2008, AN BRAS DERMATOL, V83, P39, DOI 10.1590/S0365-05962008000100005eng
hcfmusp.relation.referenceMartins Gladys Aires, 2004, An. Bras. Dermatol., V79, P521, DOI 10.1590/S0365-05962004000500002eng
hcfmusp.relation.referenceMeyer N, 2010, J EUR ACAD DERMATOL, V24, P1075, DOI 10.1111/j.1468-3083.2010.03600.xeng
hcfmusp.relation.referenceMichalek IM, 2017, J EUR ACAD DERMATOL, V31, P205, DOI 10.1111/jdv.13854eng
hcfmusp.relation.referenceMoller AH, 2015, PATIENT-RELAT OUTCOM, V6, P167, DOI 10.2147/PROM.S81428eng
hcfmusp.relation.referenceMoradi M, 2015, ARCH IRAN MED, V18, P153, DOI 0151803/AIM.004eng
hcfmusp.relation.referenceNorris D, 2017, J DERMATOL TREAT, V28, P731, DOI 10.1080/09546634.2017.1329501eng
hcfmusp.relation.referenceOgdie A, 2015, RHEUM DIS CLIN N AM, V41, P545, DOI 10.1016/j.rdc.2015.07.001eng
hcfmusp.relation.referencePuig L, 2015, J DERMATOL TREAT, V26, P7, DOI 10.3109/09546634.2013.860209eng
hcfmusp.relation.referenceReilly Associates, 2016, WPAI SCOReng
hcfmusp.relation.referenceREILLY MC, 1993, PHARMACOECONOMICS, V4, P353, DOI 10.2165/00019053-199304050-00006eng
hcfmusp.relation.referenceRomiti R, 2018, J DERMATOLOG, V17, P1eng
hcfmusp.relation.referenceRomiti R, 2017, INT J DERMATOL, V56, pE167, DOI 10.1111/ijd.13604eng
hcfmusp.relation.referenceRosen CF, 2012, RHEUMATOLOGY, V51, P571, DOI 10.1093/rheumatology/ker365eng
hcfmusp.relation.referenceSantos M, 2016, MED DECIS MAKING, V36, P253, DOI 10.1177/0272989X15613521eng
hcfmusp.relation.referenceSchaefer CP, 2015, J AM ACAD DERMATOL, V73, P585, DOI 10.1016/j.jaad.2015.06.049eng
hcfmusp.relation.referenceSnaith R, 1993, QUAL LIFE NEWSLETTER, V6, P5eng
hcfmusp.relation.referenceSojevic Timotijevic Z, 2013, J DERMATOL, V40, P797, DOI 10.1111/1346-8138.12201eng
hcfmusp.relation.referenceTang K, 2011, ARTHRIT CARE RES, V63, pS337, DOI 10.1002/acr.20633eng
hcfmusp.relation.referenceTejada CD, 2011, AN BRAS DERMATOL, V86, P1113, DOI 10.1590/S0365-05962011000600008eng
hcfmusp.relation.referenceVanderpuye-Orgle J, 2015, J AM ACAD DERMATOL, V72, P961, DOI 10.1016/j.jaad.2015.02.1099eng
hcfmusp.relation.referenceWhite D, 1999, BRIT J PSYCHIAT, V175, P452, DOI 10.1192/bjp.175.5.452eng
hcfmusp.relation.referenceWILLIAMS A, 1990, HEALTH POLICY, V16, P199eng
hcfmusp.relation.referenceWu Y, 2009, AM J CLIN DERMATOL, V10, P407, DOI 10.2165/11310440-000000000-00000eng
hcfmusp.relation.referenceZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.xeng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication830df912-b6d8-4dec-96d9-77c7eb49d3ee
relation.isAuthorOfPublication.latestForDiscovery830df912-b6d8-4dec-96d9-77c7eb49d3ee
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_LOPES_Humanistic_and_Economic_Impact_of_Moderate_to_Severe_2019.PDF
Tamanho:
499.37 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/50